Liminatus Pharma Class A Common Stock EBIT

Liminatus Pharma Class A Common Stock (LIMN) currently reports a EBIT of $-12M as of June 2026. That compares with $-1.5M in the prior-year period — down 753.3% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Liminatus Pharma Class A Common Stock's EBIT history and peer comparisons.

Liminatus Pharma Class A Common Stock's EBIT decreased from $-1.5M to $-12M — a 753.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Liminatus Pharma Class A Common Stock's EBIT of $-12M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Liminatus Pharma Class A Common Stock reported $-12M in EBIT as of June 2026. That compares with $-1.5M in the prior-year period — down 753.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-12M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Liminatus Pharma Class A Common Stock, and consider following LIMN for alerts when major investors trade the stock.